Piper Sandler analyst David Westenberg lowered the firm’s price target on Guardant Health to $30 from $40 and keeps an Overweight rating on the shares. The firm cites Guardant Health’s quarterly results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GH:
- Guardant Health price target lowered to $37 from $44 at TD Cowen
- Guardant Health price target lowered to $35 from $38 at BofA
- Guardant Health price target lowered to $45 from $50 at Canaccord
- Guardant Health sees FY24 revenue $655M-$670M, consensus $669.36M
- Guardant Health reports Q4 adjusted EPS (64c), consensus (87c)